Medtronic Sets October Annual Meeting, Details FY26 Revenue Growth of 8.4%
The Irish medical technology giant disclosed strong fiscal 2026 performance ahead of its October shareholder meeting in Galway, with organic revenue growth marking the strongest top-line performance in a decade.
Meeting Details and Voting Matters
Medtronic plc has scheduled its annual general meeting for October 15, 2026, at 8:00 a.m. local time at The Galmont Hotel & Spa in Galway, Ireland, according to a DEF 14A filing dated August 17, 2026. Shareholders of record as of August 21, 2026, are entitled to vote on six proposals, including the election of twelve directors and a non-binding advisory vote on executive compensation.
The board is recommending shareholders vote "FOR" all proposals, which also include ratifying PricewaterhouseCoopers LLP as the company's independent auditor for fiscal year 2027, renewing the board's authority to issue shares, and authorizing overseas market purchases of ordinary shares (DEF 14A filing, 2026-08-17).
Proxy voting is available through October 14, 2026, via internet at proxyvote.com or by phone at 1-800-690-6903, with earlier deadlines for shares held through the company's savings and investment plans (DEF 14A filing, 2026-08-17).
Strong Fiscal 2026 Performance
Medtronic reported revenue of $36.4 billion for fiscal year 2026, representing an 8.4% increase on a reported basis and 5.8% organic growth versus fiscal year 2025, "marking our strongest top-line performance in 10 years" (DEF 14A filing, 2026-08-17). The Cardiovascular segment delivered high-single-digit organic growth, while the Neuroscience and Medical Surgical segments grew low-single digits, and Diabetes achieved high-single-digit growth.
The company's Cardiac Ablation Solutions business reached an annualized revenue run rate of $2 billion, supported by regulatory approvals for Sphere-360 and continued demand for the Affera mapping system (DEF 14A filing, 2026-08-17). In Medical Surgical, the Hugo robot-assisted surgical system received FDA approval for minimally invasive urologic procedures and is launching across the United States.
GAAP diluted earnings per share of $3.73 increased 3.3%, while non-GAAP diluted EPS of $5.53 increased 0.7%, each versus fiscal year 2025 (DEF 14A filing, 2026-08-17). Free cash flow reached $5.4 billion, "the highest since 2022," representing a 4.6% increase year-over-year. The company returned $4.2 billion to shareholders through dividends and net share repurchases in fiscal year 2026.
Governance and Strategic Initiatives
The board established two new committees during fiscal year 2026: the Growth Committee to oversee portfolio management, R&D investments, and M&A strategy, and the Operations Committee to provide focused review of operational efficiency initiatives (DEF 14A filing, 2026-08-17).
In a significant portfolio move, the company's Diabetes business, MiniMed, completed its initial public offering in March, described as "the first phase in a multi-step plan to separate the Diabetes business from the rest of the Company" (DEF 14A filing, 2026-08-17).
The filing notes that M&A activity increased through 2026, including acquisitions of and investments in CathWorks, Scientia Vascular, Beluga Medical, CardioACC, Anteris, and Pulnovo. MarginX data shows the company is expected to report Q1 2027 results on September 1, 2026, with recent insider activity including stock awards to executives Thompson Kweli and Michelle Quinn.
This article was generated by MarginX from the DEF 14A filing on 2026-08-17. It is not investment advice.